Optimizing the hybrid capture ii human papillomavirus test to detect cervical intraepithelial neoplasia

Obstetrics and Gynecology

Volumn 100, Issue 5, 2002, Pages 972-980

  Howard, Michelle ^a   Sellors, John ^a   Kaczorowski, Janusz ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADOLESCENT; ADULT; ARTICLE; CALCULATION; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HYBRID; MAJOR CLINICAL STUDY; ONCOVIRINAE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX DISEASE; UTERINE CERVIX EPITHELIUM; UTERINE CERVIX TUMOR; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; ROC CURVE; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL LOAD;

EID: 0036854113     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/00006250-200211000-00026     Document Type: Article

References (44)

1. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
2. Franco EL. Cancer causes revisited: Human papillomavirus and cervical neoplasia. J Natl Cancer Inst 1995;87:779-80.
3. Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ 2000;163:503-8.
4. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
5. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening; results from women in a high-risk province of Costa Rica. JAMA 2000;238:87-93.
6. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-102.
7. Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 2001;357:1831-6.
8. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
9. Ho GY, Bierman R, Beardsley L, Chang C, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
10. Lancaster EJ, Banach L, Lekalakala T, Mandiwana I. Carcinoma of the uterine cervix: Results of Ka-Ngwane screening programme and comparison between the results obtained from urban and other unscreened rural communities. East Afr Med J 1999;76:101-4.
11. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996;23:707-29.
12. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
13. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, et al. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: A randomized trial. CMAJ 2000;163:701-7.
14. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163:513-8.
15. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000;96:410-6.
16. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baselines results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
17. Kiviat NB, Koutsky LA, Critchlow CW, Lorincz AT, Cullen AP, Brockway J, et al. Prevalence and cytologic manifestations of human papilloma virus (HPV) types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, and 56 among 500 consecutive women. Int J Gynecol Pathol 1992;11:197-203.
18. Nindl I, Lorincz A, Mielzynska I, Petry U, Baur S, Kirchmayr R, et al. Human papillomavirus detection in cervical intraepithelial neoplasia by the second-generation hybrid capture microplate test, comparing two different cervical specimen collection methods. Clin Diagn Virol 1998;10:49-56.
19. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167-71.
20. Ho GYF, Palan PR, Basu J, Romney SL, Kadish AS, Mikhail M, et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer 1998;78:594-9.
21. Josefsson AM, Magnusson PKE, Ylitalo N, Sørensen P, Qwarforth-Tubbin P, Andersen PK, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 2000;355:2189-93.
22. Yitalo N, Sørensen P, Josefsson AM, Magnusson PKE, Andersen PK, Pontén J, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000;355:2194-8.
23. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981.
24. Youden JW. Index for rating diagnostic tests. Cancer 1950;3:32-5.
25. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: A basic science for clinical medicine. Toronto: Little, Brown and Company, 1985.
26. Kraemer HC. Evaluating medical tests: Objective and quantitative guidelines. Newbury Park, California: Sage Publications, 1992.
27. Cox JT. HPV testing: Is it useful in triage of minor Pap abnormalities? J Fam Pract 1998;46:121-4.
28. Sherman ME, Schiffman M, Cox JT. Effects of age and human papillomavirus viral load on colposcopy triage: Data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-7.
29. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
30. Kuhn L, Denny L, Pollack A, Lorincz A, Richard RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
31. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer. Lancet 1992;339:959-60.
32. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (Pred Oncol) 1996;69:364-8.
33. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia. Lancet 1992;339:959-60.
34. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 of 3 in relation to papillomavirus infection. N Engl J Med 1992; 327:1272-8.
35. Terry G, Ho L, Jenkins D, Hills M, Singer A, Mansell B, et al. Definition of human papillomavirus type 16 DNA levels in low and high grade cervical lesions by a simple polymerase chain reaction technique. Arch Virol 1993; 128:123-33.
36. Schlecht N, Kugala S, Robitaille J, Ferreirea S, Santos M, Miyamuar RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.
37. Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
38. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations. Realistic estimates from the ASCUS-LSIL triage study. JAMA 2001;285:1500-5.
39. Clavel C, Masure M, Bory J-P, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7932 women. Br J Cancer 2001;89:1616-23.
40. Swan DC, Tucker RA, Tortolero-Luna G, Follen Mitchell M, Wideroff L, Unger ER, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HVP type. J Clin Microbiol 1999;37:1030-4.
41. Sun C-A, Lai H-C, Chang C-C, Neih S, Yu C-P, Chu T-Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of the uterine cervix. Gynecol Oncol 2001;83:95-9.
42. Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, et al. Triage of women with ASCUS and LSIL on Pap smear reports: Management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-34.
43. Meijer CJLM, Snijders PJF, van den Brule AJC. Screening for cervical cancer: Should we test for infection with high-risk HPV? CMAJ 2000;163:535-8.
44. Kiviat N. Natural history of cervical neoplasia: Overview and update. Am J Obstet Gynecol 1996;175:1099-104.